You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 開拓藥業-B逆市漲超7%,年初至今累計漲超190%
uSMART盈立智投 03-19 09:57

uSMART盈立智投3月19日消息,曾經一度腰斬65%的新股,今年翻身成"牛股"!

週五港股早盤,開拓藥業-B再度逆市大漲,截至9:46,開拓藥業-B漲7.03%,報30.6港元,繼續創歷史新高,值得注意的是,開拓藥業-B昨天收漲17.08%,年初至今累計漲超190%。

開拓藥業-B於2020年5月22日在港股上市,上市後一路陰跌,打新黨一度被深套-65%,不過近4個月開始強勢逆襲。

股價的逆襲,源自核心藥物的研發進展順利

3月11日,開拓藥業宣佈,普克魯胺在巴西進行的治療重症新冠患者的3期臨牀試驗中達到主要終點。數據顯示:普克魯胺可將重症新冠患者的死亡風險降低92%,並將平均住院時間縮短了9天。

3月5日,開拓藥業宣佈,普克魯胺治療新冠患者III期臨牀試驗獲美國FDA批準,成爲中國首款獲得美國FDA批準開展III期臨牀試驗的治療新冠的小分子藥物。

uSMART盈立智投3月12日推送:

《開拓藥業普克魯胺3期臨牀達主要終點,打新黨被套一年終解套》

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account